Lindus Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 80

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $55.2M

  • Investors
  • 29

Lindus General Information

Description

Developer of an artificial intelligence-native biopharmaceutical company designed to identify, develop, and advance drug candidates through clinical development. The company offers asset identification and selection capabilities, in-licensed drug development programs, integrated clinical trial management, and expert-led development supported by proprietary artificial intelligence systems, enabling biopharmaceutical companies and research partners to advance drug candidates more efficiently and reach key clinical development milestones.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 65 Southwark Street
  • 1st and 2nd Floors
  • London SE1 0HR
  • England, United Kingdom
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Corporate Office
  • 65 Southwark Street
  • 1st and 2nd Floors
  • London SE1 0HR
  • England, United Kingdom

Lindus Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lindus Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC (Series B) 22-Jan-2025 $55.2M Completed Generating Revenue
5. Accelerator/Incubator 10-Sep-2024 Completed Generating Revenue
4. Early Stage VC (Series A) 09-Aug-2023 Completed Generating Revenue
3. Grant 17-May-2023 Completed Generating Revenue
2. Early Stage VC (Series 3) 08-Nov-2021 $8.48M $8.48M Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2021 Completed Generating Revenue
To view Lindus’s complete valuation and funding history, request access »

Lindus Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B Preferred
Series A-2 Preferred
Series A-1 Preferred
Preference 659,361 $0.000001 $6 $6 1x $6 13.74%
Preference 43,237 $0.000001 $5.1 $5.1 1x $5.1 0.9%
To view Lindus’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Lindus Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an artificial intelligence-native biopharmaceutical company designed to identify, develop, and advance drug
Biotechnology
London, United Kingdom
80 As of 2026

New York, NY
 

Basel, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lindus Competitors (10)

One of Lindus’s 10 competitors is Formation Bio, a Venture Capital-Backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Formation Bio Venture Capital-Backed New York, NY
Roche Corporation Basel, Switzerland
Roivant Sciences Formerly PE-Backed New York, NY
Vial (Drug Discovery) Venture Capital-Backed San Francisco, CA
Novartis Corporation Basel, Switzerland
You’re viewing 5 of 10 competitors. Get the full list »

Lindus Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lindus Investors (29)

Investor Name Investor Type Holding Investor Since Participating Rounds
Balderton Capital Venture Capital Minority
SC Nation Services Venture Capital Minority
Visionaries Club Venture Capital Minority
Tech Nation Group Accelerator/Incubator
271.vc Venture Capital Minority
You’re viewing 5 of 29 investors. Get the full list »

Lindus FAQs

  • When was Lindus founded?

    Lindus was founded in 2021.

  • Where is Lindus headquartered?

    Lindus is headquartered in London, United Kingdom.

  • What is the size of Lindus?

    Lindus has 80 total employees.

  • What industry is Lindus in?

    Lindus’s primary industry is Biotechnology.

  • Is Lindus a private or public company?

    Lindus is a Private company.

  • What is the current valuation of Lindus?

    The current valuation of Lindus is .

  • What is Lindus’s current revenue?

    The current revenue for Lindus is .

  • How much funding has Lindus raised over time?

    Lindus has raised $81.3M.

  • Who are Lindus’s investors?

    Balderton Capital, SC Nation Services, Visionaries Club, Tech Nation Group, and 271.vc are 5 of 29 investors who have invested in Lindus.

  • Who are Lindus’s competitors?

    Formation Bio, Roche, Roivant Sciences, Vial (Drug Discovery), and Novartis are some of the 10 competitors of Lindus.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process